[Retracted] The Visceral Adiposity Index (VAI) and Lipid Accumulation Product (LAP) Are Predictors of Insulin Resistance and Hyperandrogenaemia in Obesity/Overweight Women with Polycystic Ovary Syndrome
BioMed Research International · 2023
DOI: 10.1155/2023/1508675 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift BioMed Research International, 2023. Verfasst von Haiyan Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Reproductive Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Hauptthemen laut MEDLINE: Insulin Resistance, Polycystic Ovary Syndrome, Lipid Accumulation Product. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
Hyperandrogenaemia and insulin resistance (IR) are the main characteristics of polycystic ovary syndrome (PCOS). Here, we study to find appropriate markers predicting IR and hyperandrogenaemia of women with PCOS in northwest China.
Methods
According to body mass index (BMI), 953 patients with PCOS were divided into two groups. All the patients underwent physical examination and ultrasonography and collected elbow vein blood. Their BMI, waist‐to‐height ratio (WHtR), waist‐to‐hip ratio (WHR), LAP, VAI, homeostasis model assessment index of insulin resistance (HOMA‐IR), and free androgen index (FAI) were calculated. Each group (normal weight and obesity/overweight) was further divided into two subgroups according to their HOMA‐IR and FAI: the IR+ subgroup/IR‐ subgroup and FAI+ subgroup/FAI‐ subgroup. Furthermore, we compared the clinical indices, hormone levels, and metabolic makers separately between these groups. The correlations between these parameters and HOMA‐IR or FAI were tested; sensitivity, specificity, and receiver‐operating characteristic (ROC) curves were calculated.
Results
In the obesity/overweight group, the VAI (best cut‐off value: 2.27, area under the curve (AUC) = 0.699) and LAP (best cut‐off value: 45.54, AUC = 0.680) were sensitive predictors of IR (sensitivity = 72 % and sensitivity = 67 % ). Additionally, the VAI (best cut‐off value: 2.13, AUC = 0.624) and LAP (best cut‐off value: 51.18, AUC = 0.582) were sensitive predictors of FAI (sensitivity = 87 % and sensitivity = 64 % ). In the normal weight group, BMI could preferably predict HOMA‐IR (AUC = 0.717, best cut‐off value: 21.62) and HOMA‐IR could preferably predict FAI (best cut‐off value: 2.11, AUC = 0.648).
Conclusion
Our data indicated that the VAI and LAP may contribute to the early identification of IR and hyperandrogenaemia in the obesity/overweight patients of PCOS. In normal weight PCOS, BMI was a better predictor to IR, and HOWA‐IR was a better predictor to FAI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Reproductive Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
ORCID-Profile: Haiyan Wang, Haozhe Cao, Jing Cao, Li Zhang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, H., Cao, H., Cao, J., & Zhang, L. (2023). [Retracted] The Visceral Adiposity Index (VAI) and Lipid Accumulation Product (LAP) Are Predictors of Insulin Resistance and Hyperandrogenaemia in Obesity/Overweight Women with Polycystic Ovary Syndrome. BioMed Research International. https://doi.org/10.1155/2023/1508675
Vancouver
Wang H, Cao H, Cao J, Zhang L. [Retracted] The Visceral Adiposity Index (VAI) and Lipid Accumulation Product (LAP) Are Predictors of Insulin Resistance and Hyperandrogenaemia in Obesity/Overweight Women with Polycystic Ovary Syndrome. BioMed Research International. 2023. doi:10.1155/2023/1508675
BibTeX
@article{Wang2023,
author = {Wang, Haiyan and Cao, Haozhe and Cao, Jing and Zhang, Li},
title = {[Retracted] The Visceral Adiposity Index (VAI) and Lipid Accumulation Product (LAP) Are Predictors of Insulin Resistance and Hyperandrogenaemia in Obesity/Overweight Women with Polycystic Ovary Syndrome},
journal = {BioMed Research International},
year = {2023},
doi = {10.1155/2023/1508675}
}
EUVIMED